News articles about Chromadex (NASDAQ:CDXC) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Chromadex earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.4325326695757 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Chromadex (CDXC) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- ChromaDex Corporation Reports 2017 Financial Results Fourth Quarter 2017 Net Revenues Increased by 69% to $7.5 … – Markets Insider (markets.businessinsider.com)
- ChromaDex’s (CDXC) CEO Frank Jaksch on Q4 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Chromadex (CDXC) Releases Earnings Results, Misses Expectations By $0.14 EPS (americanbankingnews.com)
- ChromaDex Corporation Reports 2017 Financial Results (finance.yahoo.com)
A number of analysts have issued reports on CDXC shares. HC Wainwright set a $8.00 price target on shares of Chromadex and gave the company a “buy” rating in a report on Friday, February 9th. BidaskClub downgraded shares of Chromadex from a “strong-buy” rating to a “buy” rating in a report on Friday, December 22nd. Finally, Zacks Investment Research upgraded shares of Chromadex from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a report on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $7.50.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). The company had revenue of $7.53 million for the quarter, compared to the consensus estimate of $7.50 million. Chromadex had a negative net margin of 48.68% and a negative return on equity of 69.71%. equities analysts anticipate that Chromadex will post -0.09 earnings per share for the current fiscal year.
In other news, CEO Frank L. Jaksch, Jr. sold 28,379 shares of the business’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $6.52, for a total value of $185,031.08. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Frank L. Jaksch, Jr. sold 58,400 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $6.19, for a total transaction of $361,496.00. The disclosure for this sale can be found here. Insiders own 11.59% of the company’s stock.
WARNING: “Chromadex (CDXC) Getting Somewhat Positive Media Coverage, Report Finds” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/14/chromadex-cdxc-getting-somewhat-positive-media-coverage-report-finds/2028638.html.
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.